A three-stage approach was undertaken using genome-wide, case-control, and case-only association studies to identify genetic variants associated with heart failure mortality. In an Amish founder population ( n = 851), cardiac hypertrophy, a trait integral to the adaptive response to failure, was found to be heritable ( h 2 = 0.28, p = 0.0002) and GWAS revealed 21 candidate hypertrophy SNPs. In a case ( n = 1,610)-control ( n = 463) study in unrelated Caucasians, one of the SNPs associated with hypertrophy (rs2207418, p = 8 × 10 −6
Introduction
The progression of symptoms, ventricular dysfunction, arrhythmias, and mortality remains highly variable in chronic heart failure regardless of etiology or treatment. 1, 2 This interindividual variability, the variable penetrance of inherited cardiomyopathies, 3 and epidemiologic evidence, 4 suggest that common polymorphisms might have modifying eff ects in heart failure, predisposing to certain phenotypes including the rate of progression. An integral nodal point during the development of heart failure is cardiac hypertrophy. 5, 6 Cardiac hypertrophy is heritable 7 and is a recognized risk factor for heart failure. 8, 9 In this study, we hypothesized that interindividual variability in the genetic risk factors for the hypertrophy trait may also infl uence the risk for developing heart failure or its prognosis over time. While genome-wide association studies have identifi ed potential hypertrophy-associated SNPs in various heterogeneous populations, 10,11 these have not been associated with heart failure mortality. 12 We considered a diff erent approach, by which potential hypertrophy-associated SNPs were identifi ed by GWAS in a homogeneous founder population of individuals in the absence of confounding disease that have highly similar environmental infl uences and genetic backgrounds and thus decreased noise. We hypothesized that SNPs associated with hypertrophy in this population altered the risk of heart failure and/or heart failure mortality. While these SNPs from the founder population might be considered risk factors for so called "physiological hypertrophy, " it has been proposed that the structural, metabolic and genomic events associated with physiologic and pathologic hypertrophy represent a continuum that includes commonalities. 13, 14 Th us, variability in the hypertrophic response may lead to subsequent variability in the adaptive and maladaptive events of progressive heart failure. For example, subjects genetically predisposed to excessive pathological hypertrophy in the face of a uniform stress might progress more readily to heart failure, or deteriorate more rapidly once heart failure has developed. On the other hand, a genetic predisposition to protective hypertrophy as develops in trained athletes might be resistant to heart failure or its adverse sequelae. In considering these possibilities we designed a study that would identify potential genetic determinants of cardiac hypertrophy in a normal founder population, and then specifi cally explored which of these impacted heart failure risk and progression.
Methods

Patient populations and echocardiography
Th e founder population consisted of 851 Old Order Amish individuals ages 20-80 years recruited from Lancaster, PA as part of the Heredity and Phenotype Intervention Heart (HAPI Heart) Study. Th is cohort of apparently healthy individuals has been previously described in detail. 15 Th e genealogy of all participants was known based on a formalized record system, which has been confi rmed by genetic studies. 16 Th e heart failure cohort was established by the NHLBI-sponsored Specialized Center of Clinically Oriented Research (SCCOR) and consisted of unrelated prospectively enrolled patients from the University of Cincinnati College of Medicine ( n = 1,302) and the University of Maryland School of Medicine ( n = 308). Th is group consisted of white patients between the ages of 18 and 90 years with left ventricular ejection fraction (LVEF) <35%, and a diagnosis of ischemic or nonischemic cardiomyopathy. Patients with valvular lesions or myocarditis, or those with hypertrophic cardiomyopathy, were not included. Th e control group has been previously described and consisted of 463 asymptomatic Caucasians with normal electrocardiograms and echocardiograms. 17 Left ventricular mass (LVM) was calculated from 2D echocardiography according to the American Society of Echocardiography recommendations. 18 LVM index (LVMI) was determined from the LVM divided by the calculated body surface area. Only samples with call rates >93% on both microarrays ( Nsp I and Stly I digestions) were used for analysis. Th e mean call rate of the 851 resulting samples was 97.5%. Marker call rate was then assessed across the acceptable samples, and markers with a call rate >90% across samples and minor allele frequency >5% were considered for analysis ( n = 361,034). Quantitative trait association analysis of LVMI using a variance component approach was then performed as implemented in SOLAR soft ware (Southwest Foundation for Biomedical Reserch, San Antonio, TX, USA). 20 We used the measured genotype approach, in which we estimated the likelihood of additive, recessive and dominant genetic models given the pedigree structure. 21 Within each model, we simultaneously estimated the eff ects of age and sex. Parameter estimates were obtained by maximum likelihood methods, and the signifi cance of association was tested by the likelihood ratio test. Selection of candidate SNPs from the Amish GWAS was performed in two steps. First we selected our top 13 loci based solely on a p -value of ≤10 −6 in our additive model. We then looked at our association results based on dominant and recessive models and selected another 10 candidate loci based on SNPs with a combination of lowest p -value and consistency across all three genotypes.
Hypertrophy-Associated Polymorphisms Ascertained in a Founder
Follow-up genotyping and association analysis in the normal and heart failure cohorts Because the identifi ed LVMI candidate SNPs were derived in the Amish, who are Caucasian, only patients who were selfidentifi ed as "white" or "Caucasian" were included in follow-up genotyping in the normal and heart failure cohorts from the general population. Of the SNPs found to be associated with LVMI in the Amish by the aforementioned criteria, several were in the same gene and were in 100% linkage disequilibrium (LD). In these situations one SNP from the group was chosen for further genotyping. Th us 21 SNP positions were genotyped for each subject in the normal and heart failure cohorts. TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA) were utilized to detect the allele at each of the SNP sites identifi ed in the Amish hypertrophy GWAS from DNA from the normal and heart failure cohorts. Th ese assays were performed on an Applied Biosystems Model 7900HT Fast system, using the probes and primers supplied by the manufacturer for allelic discrimination, with a call rate of >95%. Hardy-Weinberg Equilibrium (HWE) was assessed using a chi-square test for all SNPs with allele frequencies >0.01. Diff erences in the distribution of alleles between control and case cohorts were determined by Chi-square tests. We utilized a prespecifi ed mortality outcome which consisted of all-cause mortality, cardiac transplant, and implanted cardiac defi brillator shock for ventricular tachycardia. Relative risks were obtained by Cox Proportional Hazards modeling using a genotypic model both before and aft er adjustment for age at diagnosis and sex. All analyses were carried out using the R Statistical Language ( http://www.R-project.org ). Two-tailed tests and an alpha level = 0.05 were used to assess statistical signifi cance.
Estimation of linkage disequilibrium and conserved sequence analysis LD between the genotyped SNPs was calculated as r 2 . 22 LD ( r 2 ) relationships between the genotyped SNPs and those of CEU subjects from the HapMap (phase 1 and 2 datasets, www.hapmap. org ), were calculated using Haploview. 23 Estimates of sequence similarity and conservation was based on lod scores calculated by the PhastCons program (PhastCons Conserved Elements, 28-way Vertebrate Multiz Alignment, University of California Santa Cruz, Santa Cruz, CA, USA) provided by UCSC genome browser.
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Results
Th e demographic characteristics and echocardiography results for the Amish cohort ( n = 851) are shown in Table 1 . Th e mean LVM was 152 g (interquartile range 45.0 g) and the mean LVMI was 82 g/cm 2 (interquartile range 23.3 g/cm 2 ). In this founder population, the heritability ( h 2 ) for LVM was calculated to be 0.32, p < 0.0001, and for LVMI = 0.28, p = 0.0002. GWAS revealed 21 nonredundant SNPs associated with LVMI under an additive, dominant or recessive model using the specifi ed criteria ( Table 2 ). Typically, the diff erence in LVMI between the two homozygous states was ~10 g/m 2 . In some cases, there was a gene-dose dependency for the three possible genotypes. For example, the HTR2A SNP had LVMI values of 94.4, 89.0, and 84.3 g/m 2 for subjects who were homozygous for the minor allele, heterozygous, and homozygous for the major allele, respectively ( Table 2 ) . In other cases, the LVMI values for the homozygous minor (or major) allele and heterozygosity were similar, but clearly diff ered from the other homozygous allele. For example, for the FGF1 SNP the minor allelic state and heterozygosity had LVMI values of 86.6 and 87.3 g/m 2 , while the homozygous major allelic state had an LVMI value of 106.3 g/m 2 ( Table 2 ). Assays were developed for the list of 21 candidate hypertrophy SNPs to ascertain potential associations with heart failure risk and mortality in the case-control, and case-only studies, respectively. Th e healthy control population consisted of 463 Caucasian volunteers who were 60% female, with a mean (±SD) age of 49 ± 12.2 years and LVEF of 59 ± 9.9%. Th e demographic characteristics for the 1,610 patients in the heart failure cohort are shown in Table 3 . Th e mean age was 52.6 years at enrollment, the average follow-up time was 5.8 years, and there were 711 events. Th e genotypes of the control subjects and the heart failure patients are shown in Tables 4 and 5 , respectively. Genotypes for one SNP in the control cohort (rs3729931) and two in the heart failure cohort (rs2207418 and rs4686148) showed some deviation from HWE (Supplementary Table 1) .
In comparing the distribution of alleles between normal controls and heart failure patients (Supplementary of the three genotypes ( p = 0.0016). In the unadjusted analysis, the relative risk of heart failure for the GG genotype is 1.98 (95% CI = 1.35 to 2.90, p = 0.0004). Adjusted for age and sex, the association was maintained with RR = 1.85 (95% CI = 1.25 to 2.73, p = 0.0019) for the homozygous minor allele. For the other Amish hypertrophy-associated SNPs, no p -value was less than 0.12 for the genotype distribution analysis between cases and controls (Supplementary Table 2 ). Th ere was no association between the Amish hypertrophy-associated SNPs and LVMI in the heart failure cohort (data not shown).
For the mortality association analysis in the heart failure cohort, we found that three of the LVM candidate SNPs were associated in the unadjusted analysis, and two in the age and sex adjusted analysis ( Table 6 ) . Th e most robust association with mortality was again with rs2207418. In heart failure, the homozygous minor allele for this SNP was associated with mortality with a hazard ratio of 1.57 (95% CI = 1.25 to 1.97, p = 0.00013) in the unadjusted model, and when adjusted for age and sex this ratio for the homozygous minor allele was virtually the same, being 1.51 (95% CI = 1.2 to 1.9, p = 0.0004). Interestingly, in the Amish this SNP was associated with an increased LVMI of ~13 g/m 2 , when compared to the heterozygotes or those homozygous for the major allele ( Table 2 ). Th us, these fi ndings are consistent across three studies in that the trait, risk, and hazard are found only with minor allele homozygosity. Th e other SNP associated with increased risk of mortality was in COL17A1. In the unadjusted analyses the G allele is associated with increased risk (HR = 1.71, p = 0.0051); in the adjusted analysis the eff ect size was similar (HR = 1.62, 95% CI = 1.10 to 2.37) with a modest level of signifi cance ( p = 0.013). Th ere were no homozygous COL17A1 GG subjects. Th e rs152528 SNP in FGF1 was marginally signifi cant for protection (HR = 0.852) in the unadjusted analysis but this was only observed with the heterozygous state. Aft er adjustment, the association with the heterozygous state approached signifi cance (HR = 0.855, 95% CI = 0.728 to 1.00, p = 0.056). No signifi cant association was found for "carrier" status for the FGF1 SNP (data not shown).
rs2207418 is located on chromosome 20p12 and is within a repeat element that belongs to MIR family of short interspersed nuclear elements (SINE), and is >500 kb away from the nearest known genes (see HapMap release 24 NCBI B36 assembly). Th ere are fi ve annotated genes, however, within ~2 Mb of this SNP: C20orf94 , BTBD3 , SNAP25 , MKK5 , and JAG1 . Analysis of LD between rs2207418 and HapMap SNPs within and near these Had event (N) 711 Table 3 . Demographic characteristics of the heart failure cohort (mean ± SD).
fi ve genes (20 kb 5Ј and 3Ј to the fi rst and last known exons) did not reveal any SNP with strong LD to rs2207418 (all pairwise r 2 < 0.10, Supplementary Figures 1-5) . A further analysis of this region was performed to examine elements highly conserved between homologous sequences from 28 vertebrate species ( Figure 1 ). We found that this region encompassing rs2207418 has multiple conserved elements across these species. One region (~15 kb 3Ј) is also found in fi sh, with a lod score = 1,208 ( Figure 1 ). Th is degree of conservation suggests that this region may serve an important function that has not been previously recognized, such as an enhancer or repressor element for one of the fi ve aforementioned genes, or other genes that are more remote.
Discussion
In an eff ort to identify variants that associate with heart failure mortality, we took a three-stage approach that began with an unbiased GWAS for a relevant trait (cardiac hypertrophy) in a founder population. In this group of apparently healthy subjects LVM and LVMI values were normally distributed with estimated heritable components of 32% and 28%, respectively. Th e list of associated SNPs generated from this analysis was then utilized in a case-control study for heart failure risk, and a case study with mortality as the end point, in cohorts of unrelated individuals. Because of the a priori evidence from the founder study for the 21 SNPs having association with a relevant trait (and the small number of SNPs being considered) we did not perform any corrections for multiple comparisons in the heart failure trials. Of these SNPs, the homozygous rs2207418 genotype was associated with an 85% increased risk for heart failure in the case-control study, which was highly signifi cant ( p = 0.0019 in the adjusted analysis). In the mortality analysis this same SNP and two others showed some evidence of association, with rs2204718 having the most robust fi ndings with a 51% increase in mortality at a significance level of p = 0.0004 for the homozygous GG genotype. Th is SNP is in a region of chr 20 (position 11124903) which consists of a SINE. While the SNP lies within a haplotype block (covering ~100 kbp, data not shown) this region still remains in the SINE, thus the LD has no readily inferred biologic implications. Five genes lie within 2 mbp of rs2204718: JAG1 , C20orf94 , BTBD3 , SNAP25 , and MKK5. However, the LD between rs2204718 and those within these fi ve genes is low, with the most intriguing being the intronic SNP rs6108653 in JAG1 , whose protein product JAG1 is a ligand for the Notch1 receptor. JAG1 and Notch1 are critical for normal cardiac and great vessel development. 25 Mutations of JAG1 are associated with severe congenital cardiac defects including Alagille syndrome, 26, 27 and tetralogy of Fallot, 28 however these represent developmental defects of the great vessels. Furthermore, LD between rs2204718 and rs6108653 is low (r 2 < 0.01). We have considered that rs2204718 may lie within (or is in LD with another variant) in a previously unrecognized regulatory element of the aforementioned fi ve genes, or more distant genes. In support of this notion, the SINE where rs2204718 is located represents a highly conserved region amongst primates and mammals, and a smaller segment is also conserved in other vertebrates such as fi sh ( Figure 1 ). Th ese fi ndings are consistent with the concept that this region serves an important role in gene regulation, likely as an enhancer or repressor element.
Although the case-control and case-only trials are related (the same heart failure cases) it is important to recognize the consistency of the fi ndings with rs2204718 across all three studies. In the Amish hypertrophy study, the SNP was associated with an increased LVMI ( p = 8.8 × 10 −6 ) in the homozygous (minor allele) state. In the case-control study, this same genotype was associated with a signifi cant risk of heart failure ( p = 0.0019), and in the case mortality study it was also associated with a highly signifi cant risk of death ( p = 0.0004). Th is consistency lends credence to our assertion that rs2204718 represents a marker for heart failure risk and mortality in Caucasians. Of note, the minor allele is also present in those of African and Asian descent at frequencies comparable to those of Europeans (see HapMap phase III/release 2), so these results may also be applicable for those populations as well. Th e association with the COL17A1 SNP rs1320448 was signifi cant in the Amish hypertrophy cohort ( p = 1 × 10
), but the minor allele frequency in the Amish (~0.06) was ~10-fold higher than in either of the unrelated Caucasian cohorts. Th ere was no association with risk in the case-control study, and the mortality association was restricted to 19 subjects who carried a minor allele and had somewhat modest statistical support with an adjusted p -value of 0.013. Taken together, we would consider this SNP to be of minor, if any, importance in heart failure mortality in those of European descent. Interestingly, both Asian and African populations show higher minor allele frequencies of rs1320448 compared to Europeans, so this SNP may be more relevant in these populations. COL17A1 encodes type XVII collagen, which is not expressed in the heart or great vessels. Mutations of COL17A1 have been associated with epidermolysis and pemphigoid lesions, 29 but to our knowledge no associations between COL17A1 variants and cardiac disease have been reported.
Conclusion
In summary, we have identifi ed candidate SNPs associated with cardiac hypertrophy in an Amish founder population. Th ese were genotyped in case-control and caseonly heart failure cohorts with the latter focusing on mortality. In a highly conserved SINE region on chromosome 20p12, a SNP was associated with hypertrophy in the Amish, heart failure risk in the casecontrol study, and mortality in patients with heart failure. Patients with this SNP who are at high risk for progression/death might be considered for more aggressive therapy, but this will need to be addressed with additional clinical studies. Table 6 . SNPs associated with mortality in the heart failure cohort .
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